Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747302 · ClinicalTrials.gov registry record · NA
HPV Message Testing and Social Media Campaign
A NA study of Human Papilloma Virus and Vaccine, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 1,043
- Enrollment target
- 1
- Study location
NCT03747302: Completed NA study of Human Papilloma Virus and Vaccine, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03747302 is a NA study of Human Papilloma Virus and Vaccine that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1,043 participants, below the 8,415-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03747302, a NA study of Human Papilloma Virus and Vaccine, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,043 participants
- Enrollment target
- 1
- Study location
Study Summary
This project involves a social media campaign to increase parent's knowledge and acceptance of the HPV (human papillomavirus) vaccine. The current vaccine protects against nine types of HPV, including seven that are known to cause cancer. The Centers for Disease Control and Prevention (CDC) estimates that the current HPV vaccine could prevent 90% of cancer cases caused by HPV, including cases of cervical cancer, oropharyngeal (mouth and throat) cancer, anal cancer, and others. About 150 and 104 cases of HPV-associated cancers are diagnosed each year in New Hampshire and Vermont, respectively-many of which could be prevented through vaccination. Currently, only 49.8% of New Hampshire adolescents and 44.3% of Vermont adolescents were not up-to-date for HPV vaccination as of 2016. This social media campaign is testing a set of campaign messages with parents locally and nationally to see which messages are most effective in improving their knowledge and acceptance of the vaccine. A study survey link will monitor the number of people reached and will measure parental intention to get their children vaccinated against HPV.
Primary Outcome
Change in Attitudes about HPV vaccine: Pre to post test comparison of summated 9 items measured on a 7-point scale of HPV vaccine attitudes. Scores range from a minimum of 9 to a maximum of 63. Higher scores indicated more positive attitudes toward HPV vaccination. Change was calculated from two time points, the later time point(\<1 hour post messaging intervention) minus value at baseline.
Conditions Studied
Interventions
- OTHER Social Media Message about HPV and HPV vaccine
- OTHER Social media message about risk of electronic cigarettes.
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2019-09-09 |
| Phase | NA |
What the finished NCT03747302 record still lists
NCT03747302 is an interventional study that assigns participants to a tested intervention. Its 1,043 participants enrollment target places it among the larger protocols in the corpus, below the 8,415-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 2 interventions - of which Social Media Message about HPV and HPV vaccine is the first listed.
NCT03747302 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT03747302 about?
NCT03747302 is a clinical study titled "HPV Message Testing and Social Media Campaign". This project involves a social media campaign to increase parent's knowledge and acceptance of the HPV (human papillomavirus) vaccine. The current vaccine protects against nine types of HPV, including seven that are known to cause cancer. The Centers for Disease Control and Prevention (CDC) estimate...
What is the current status of trial NCT03747302?
This trial is currently completed. It is a NA study. The enrollment target is 1,043 participants. The study started on 2018-12-12. Estimated completion is 2019-09-09.
What conditions does trial NCT03747302 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Vaccine.
What interventions are being tested in trial NCT03747302?
The interventions under investigation include: Social Media Message about HPV and HPV vaccine (OTHER), Social media message about risk of electronic cigarettes. (OTHER).
Who is sponsoring clinical trial NCT03747302?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03747302 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03747302's enrollment target sits among peer trials
1,043 6th of 39 higher than 34 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
RECRUITING · NA
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Impact of Standing Orders Optimization
ACTIVE NOT RECRUITING · NA
-
Development of a Self-collection Device for Cervical Cancer Screening
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI